|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (1986)) |
IUPAC Name ![]() |
| 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 5217 | famotidine |
Synonyms ![]() |
| Gaster® |
| MK-208 |
| Pepcid® |
Database Links ![]() |
|
| BitterDB Ligand | 101 |
| CAS Registry No. | 76824-35-6 |
| ChEBI | CHEBI:4975 |
| ChEMBL Ligand | CHEMBL902 |
| DrugBank Ligand | DB00927 |
| PubChem CID | 5702160 |
| Search Google for chemical match using the InChIKey | XUFQPHANEAPEMJ-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | XUFQPHANEAPEMJ |
| Search PubMed clinical trials | famotidine |
| Search PubMed titles | famotidine |
| Search PubMed titles/abstracts | famotidine |
| Wikipedia | Famotidine |
| Comments |
| Famotidine is a histamine H2 receptor antagonist. The drug is poorly soluble in the low pH of the stomach so suffers from poor bioavailability. Low dose (10-20 mg) famotidine is available over-the-counter in some countries. Marketing of a combination of famotidine with antacids magnesium hydroxide and calcium carbonate (Pepcidtwo®) has been officially discontinued in the UK (2015). |